DENALI THERAPEUTICS INC (DNLI:NASDAQ)
$19.45 0.78 (4.1778%)
Analysed DENALI THERAPEUTICS INC (DNLI:NASDAQ) News Sources
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
07-08-2026
yahoo.com
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
20-08-2026
yahoo.com
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
20-08-2026
yahoo.com
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
15-07-2026
yahoo.com
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
07-08-2026
moby.co
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
09-07-2026
yahoo.com
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
27-07-2026
yahoo.com
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
13-08-2026
fool.com
Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?
09-10-2026
yahoo.com
Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?
10-10-2026
yahoo.com
What is the current price of DENALI THERAPEUTICS INC (DNLI:NASDAQ)?
The current price of DENALI THERAPEUTICS INC (DNLI:NASDAQ) is $19.45.
DENALI THERAPEUTICS INC (DNLI:NASDAQ) absolute price change since previous trading day?
The absolute price change of DENALI THERAPEUTICS INC (DNLI:NASDAQ) since the previous trading day is $0.78.
DENALI THERAPEUTICS INC (DNLI:NASDAQ) percentage price change since previous trading day?
The percentage price change of DENALI THERAPEUTICS INC (DNLI:NASDAQ) since the previous trading day is 4.1778%.
What is the most recent average sentiment score for DENALI THERAPEUTICS INC (DNLI:NASDAQ)?
The most recent average sentiment score for DENALI THERAPEUTICS INC (DNLI:NASDAQ) is 57 out of 100.
What is the most recent average sentiment for DENALI THERAPEUTICS INC (DNLI:NASDAQ)?
The most recent sentiment for DENALI THERAPEUTICS INC (DNLI:NASDAQ) is .
SEC-8K** Filing Available For DENALI THERAPEUTICS INC (DNLI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.